Kornimate/medical-research-clean huggingface dataset:
awareness of osteoporosis in patients with hypothyroidism

Conditions: Hypothyroidism; Osteoporosis; Osteoporosis Risk

Summary: osteoporosis is a condition that describes compromised skeletal microarchitecture in general, with clinical signs of decreased bone mineral density. patients with hypothyroidism are at increased risk for developing osteoporosis. identifying whether multiple sclerosis patients have information and awareness about this disease is crucial. this study is aimed to investigate awareness and knowledge of osteoporosis in patients with hypothyroidism.

osteoporosis is a common disease of bone loss. the reduced bone strength predisposes an increased risk for fractures in older individuals. it can affect people from different ethnicity. many factors increase the risk of osteoporosis, including age, postmenopausal state, glucocorticoid use, low body weight, calcium, vitamin d, immobility, and chronic inflammation. patients with multiple sclerosis are at high risk of developing osteoporosis due to chronic inflammation and their medications. patients' knowledge and awareness about osteoporosis are essential for early detection, implementation of lifestyle changes, and treatment compliance. this study aimed to investigate osteoporosis awareness and knowledge about osteoporosis in patients with hypothyroidism.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hypothyroidism * must be between the ages of 18 and 99 * must give consent to participate in the study exclusion criteria: • not giving consent
exercise and low back pain

Conditions: Healthy Volunteers With and Without Chronic Low Back Pain

Summary: evaluation of the effectiveness of an individually educated exercise program for the lower back at home in employees over a period of 20 weeks. we hypothesize that regular exercise for the lower back results in greater improvements of low back strengths compared to controls.


Eligibility criteria:
inclusion criteria: * men and women * age between 18 and 67 years exclusion criteria: * beeing currently involved in an exercise program for the lower back * known drug or alcohol abuse * any disease that excludes the participation in an exercise program * clinical relevant acute or chronic infections * pregnant women
a study of tesetaxel plus capecitabine in patients with solid tumors

Conditions: Solid Tumor

Summary: this study is being performed to confirm the safety of tesetaxel 27 mg/m2 (day 1) in combination with capecitabine 2000/mg/m2/day (in 2 equally divided doses on days 1 through 14) in a 21-day cycle.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * confirmed diagnosis of a solid tumor malignancy, excluding lymphoma * chemotherapy-naïve or previously treated with not more than 1 non-taxane-containing chemotherapy (enrollment of patients with a history of prior taxane therapy in the adjuvant setting is allowed provided at least 6 months have passed since the conclusion of that therapy.) * ecog performance status of 0 or 1 * adequate bone marrow, hepatic, and renal function * at least 3 weeks and recovery from effects of prior surgery and anticancer therapy, with resolution of any toxicity to not more than grade 1 exclusion criteria: * brain metastasis or leptomeningeal disease * second cancer (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which patient has been disease-free for 5 or more years) * known history of human immunodeficiency virus infection or hepatitis b or hepatitis c infection * recurrent diarrhea, defined as more than 3 episodes than is usual in any 24-hour period within the 30 days prior to enrollment in this study * significant medical disease other than cancer * neuropathy at least grade 2 * difficulty swallowing * malabsorptive disorder * need for other anticancer treatment while receiving study medication * need to continue any regularly-taken medication that is a potent inhibitor or inducer of the cyp3a pathway or p-glycoprotein activity. a washout period of at least 2 weeks is required prior to the first dose of study medication. * pregnancy or lactation * history of hypersensitivity to tesetaxel, capecitabine, 5-fluorouracil, or any of their components

Keywords: solid tumor malignancy, excluding lymphoma
characterization of circulating and tumor-infiltrating immune cells in malignant brain tumors

Conditions: Brain Tumor, Primary; Brain Tumor - Metastatic

Summary: the goal of this observational study is to characterize the circulating leukocyte profile and the immune t cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the oncological outcome. participants will be subjected to blood sampling before surgery and for 12 months of follow-up. additional sampling and analysis will be performed on tumor samples.

high-grade gliomas are the most frequent type of primary brain tumor in adults, and among them, glioblastoma multiforme (gbm) is the most malignant with an associated poor prognosis. although significant advances have been achieved in gbm biology comprehension, patients' life expectancy is still limited to 18 months. brain metastases (bm) are the most frequent neoplasm in the cns; it is estimated that up to 14% of all newly diagnosed cancers will soon or later metastasize into the brain. a variety of mechanisms to escape a tumor-specific t cell-mediated immune response have been identified in glioma and other cancer entities. this project is an observational, prospective, monocentric study on patients candidates for neurosurgical procedures for brain malignant tumors with additional collection of biological material. with the present study, we aim to characterize the phenotype of both circulating- and tumor-infiltrating- immune cells at the diagnosis and their changes during disease progression and after treatment in primary and secondary brain tumors. samples will be taken at baseline (before surgery) and at time-points: 3, 6, 9, 12 months

Eligibility criteria:
inclusion criteria: * adult patients (≥18 years) * able to express informed consent * with primary or secondary malignant brain tumor * requiring neurosurgical treatment (radiosurgery, stereotactic biopsy, surgery) exclusion criteria: * patients who do not meet inclusion criteria.

Keywords: immunophenotype primary and secondary brain tumor
sequential compression devices for treatment of restless legs syndrome

Conditions: Restless Legs Syndrome

Summary: the purpose of this study is to determine if sequential compression devices (scd) when worn for an hour per day by patients suffering from restless legs syndrome (rls) are helpful for the improvement of the rls symptoms and sleep.

restless legs syndrome (rls) is a highly vexing problem manifested by sensory and motor symptoms that disrupt sleep onset or sleep maintenance. rls is the second most common sleep disorder and occurs with an estimated prevalence of 10% in the general population. the sleep disruption results in daytime symptoms such as excessive daytime sleepiness (eds) and mood changes. there are no consistently reliable treatment alternatives. there is an urgent need for new, innovative treatment strategies because available pharmacological treatments often stop working over time or are associated with unacceptable side effects. an effective nonpharmacological treatment would be a highly attractive alternative. anecdotally, patients have reported that use of sequential compression devices (scd) prescribed for prophylaxis of deep vein thrombosis can have a positive effect on rls symptoms. because this nonpharmacological alternative is available, safe, and affordable, further investigation is warranted. simply stated, the null hypothesis is that scd therapy does not have an impact on rls symptoms. patients will be randomized to wearing scds or sham scds for an hour each day prior to the usual onset of the rls symptoms. at baseline and at monthly follow-ups for 3 to 4 months, participants will complete questionnaires to assess the severity of the rls symptoms, their daytime sleepiness, and the impact of the rls on quality of life.

Eligibility criteria:
inclusion criteria: * age greater than 17 years with a reliable diagnosis of rls in accordance with the international classification of sleep disorders, revised diagnostic and coding manual of the american academy of sleep medicine. exclusion criteria: * age less than 18 years * unstable medical conditions that may interfere with the requirements of the study (for example uncontrolled diabetes mellitus, symptomatic asthma, congestive heart failure with symptoms of pulmonary edema), and mental or physical limitations (including dementia) that would preclude data collection on questionnaires or wearing the scd. * other medical conditions that would serve as exclusion criteria are those where increased venous or lymphatic return is undesirable. these specific conditions are known or suspected acute deep vein thrombosis, thrombophlebitis, severe congestive heart failure, pulmonary edema, severe arteriosclerosis, active infection such as gangrene, recent vein ligation or skin graft, or extreme deformity of the legs.

Keywords: restless legs syndrome sequential compression device sleep quality quality of life
evaluation of the clinical impact of corticosteroid duration on sars-cov-2 (covid-19 who)

Conditions: Covid 19

Summary: the purpose of this project is to evaluate the clinical impact of the use of glucocorticoids beyond 10 days for patients with critical covid-19 at mdmc.

the purpose of this project is to evaluate the clinical impact of the use of glucocorticoids beyond 10 days for patients with critical covid-19 at mdmc. glucocorticoids have become standard of care for critical covid-19 patients, with a mortality benefit shown in several recent randomized control trials. critical covid-19 can lead to ards, in which the use of glucocorticoids has uncertain benefit beyond 10 days. studies have shown increased harm in the use of these agents in persistent ards (≥14 days). additionally, studies supporting the use of steroids in covid-19 only used steroids for a limited time (up to 10 days). given that these agents can possibly lead to increased patient morbidity and mortality, prolonged use of glucocorticoids is not without risk. to date, there have been no studies evaluating the clinical impact of glucocorticoid use beyond 10 days for treatment of critical covid-19.

Eligibility criteria:
inclusion criteria: * \> 18 years of age * icu admission at any time during first hospital admission for covid-19 * covid-19 diagnosis * dexamethasone, hydrocortisone, or methylprednisolone therapy for sars-cov-2 infection exclusion criteria: * prior icu admission before study start date * death or hospice before day 11 of hospital admission * still admitted at time of data analysis from index admission
mri as an alternative to ct for exploration of acute abdominal pain in young women

Conditions: Acute Abdominal Pain; Pelvic Pain

Summary: objective : to demonstrate diagnostic performances of magnetic resonance imaging (mri) as compared to computed tomography (ct) as a second intention imaging modality in young women with acute non traumatic abdominopelvic pain and non contributive ultrasonography.

methods : consecutive women aged 18-40 years old with acute abdominopelvic pain referred to ct by the emergency physician or gynaecologist after a non contributive ultrasonography will be included. after obtaining informed consent, all patients will undergo standard ct followed by an additional mri examination, performed using a short mri protocol and within 6 hour from ct. the gold standard or reference diagnosis will be established in consensus by an expert panel at 3 months follow up using a standardized diagnosis form. a retrospective reading will be performed independently for ct and mri by radiologists blinded to the reference diagnosis, using the same standardized diagnosis form. ct and mri accuracies will be compared.

Eligibility criteria:
inclusion criteria: * women aged 18-40 years old * women referred to ct following a non contributive ultrasonography * women with acute non traumatic abdominopelvic pain (less than 5 day-duration) * women with informed consent * women with affiliation to health insurance exclusion criteria: * women who underwent abdominopelvic surgery in the previous month * suspicion of vital emergency such as shock preventing any delayed management caused by mri examination * contra-indication to mri, including pace maker, ferro-magnetic material, foreign bodies with risk of mobilization during mri examination * women yet included in the study or included in another study * women pregnant (positive beta chorionic gonadotrophic hormone testing) or breastfeeding * women unable to undergo informed consent (vulnerable or protected by law)

Keywords: mri acute abdominal pain pelvic pain diagnostic performance young women
assessment of the clinical efficacy of the heart spectrum blood pressure monitor for diagnosis of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: question: is 12-lead electrocardiography (ecg) the most accurate and convenient diagnostic method for atrial fibrillation (af)? findings: the heart spectrum blood pressure monitor can be used at home, and is capable of determining the occurrence of af. three measurement methods were used in this study. the sensitivity, specificity, ppv, and npv of the methods used are between 90% and 100%, and the heart spectrum blood pressure monitor can be effectively applied to af detection. meaning: the heart spectrum blood pressure monitor can be used at home and can replace the need for an in-office ecg, thereby accomplishing meaningful telecare.

importance: atrial fibrillation (af) is the most common arrhythmia. the most common diagnostic method, 12-lead ecg, can record episodes of arrhythmia from which the type and severity can be determined. the heart spectrum blood pressure monitor (p2, ostar meditech corp.) is used to measure cardiovascular pressure change, with fast fourier transform (fft) analysis, to obtain the heart rate frequency variability and accurate blood pressure data. objective: to compare the diagnostic efficacy of the heart spectrum blood pressure monitor with a 12-lead ecg in patients with af. three measurement methods were used in this study: blood pressure, mean arterial pressure (map) which is calculated from individual blood pressure as constant pressure, and a constant pressure 60 mmhg, in order to analyze the heart index and compare it with simultaneous 12-lead ecg. design: the physician used a 12-lead ecg and the heart spectrum blood pressure monitor simultaneously. the heart spectrum blood pressure monitor used an fft analysis for the diagnosis of af; the findings were compared with the readings from the 12-lead ecg. setting: this unblinded clinical trial was conducted at the emergency room of taipei medical university hospital. participants: twenty-nine subjects with af and 33 without af, aged 25 to 97 years (mean: 63.5 years), were included. intervention(s) for clinical trials subjects who had been exposed to high frequency surgical equipment during testing, those with cardiac pacemakers or implantable defibrillators, and pregnant women were excluded. trial registration: tmu jirb no.: n201510061

Eligibility criteria:
inclusion criteria: * subjects older than 20 years of age who had been diagnosed with af using 12-lead ecg, or were healthy (without af) were included. exclusion criteria: * subjects who had been exposed to high frequency surgical equipment during testing, those with cardiac pacemakers or implantable defibrillators, and pregnant women were excluded.

Keywords: heart spectrum blood pressure monitorheart spectrum
mexican initiative of patients with osteoarthritis and rheumatoid arthritis (impactar)

Conditions: Physical Disability; Joint Function Disorder; Axis IV Problems Economic; Compliance Behavior; Complications; Arthroplasty

Summary: the purpose of this study is to evaluate quality of life, degree of disability, treatment patterns and economic impact of hand and knee osteoarthritis and rheumatoid arthritis in mexico.

the osteoarthritis (oa) is a chronic and degenerative disease of multifactorial etiology, characterized by the gradual loss of articular cartilage. it is a question of one of the most common rheumatic disorders in the population, is the most habitual reason of pain and disability in the major adults and the first reason of surgeries of articular replacement. in mexico, in a study of national area, the prevalence of locomotives manifestations was 26 %, with predominance in the women. nowadays criteria exist for the classification of the oa, based on epidemiological studies, for the knee, the hip and the hand. basically they have been established to homogenize studies of clinical epidemiological type. in other hand, the rheumatoid arthritis (ra) is an inflammatory, chronic, systemic disease that has more prominent manifestations in the diarthrodial joints. the disease have a wide range of characteristics, from the progressively chronic disease with variable degrees of destruction to articulate up to the extra-articular manifestations clinically evident. demographically, the ra is the most common form of inflammatory arthritis and affects approximately 0.5 to 1 % of the world population, with an economic impact comparable with arterial coronary disease. the national institute of geographical statistics (inegi) thinks that in mexico the population of major adults will double in the next decades, for what the impact of these rheumatic disorders will be serious and will turn into a problem of public health. based in the previous information, the mexican initiative of patients with oa and ra (impactar), will on patient interview to increase the knowledge regarding the number of affected adults and the current treatment strategies. this will be the first mexican registry related with osteoarticular diseases.

Eligibility criteria:
inclusion criteria: * patients \> 18 years with diagnosis of oa or ra according to the criteria of the american college of rheumatology (acr). exclusion criteria: * patients with precedents of fractures; carrying patients of chronic diseases who limit them in the functional capacity.

Keywords: osteoarthritis rheumatoid arthritis disability joint function
influence of autonomy on motor learning in people with parkinson's disease

Conditions: Parkinson Disease

Summary: the goal of this clinical trial is to explore the benefits of autonomy supported learning in patients with parkinson's disease. the main questions to answer are: * whether autonomy supported learning can benefit motor learning in pd patients * whether autonomy supported learning can enhance intrinsic motivation and/ or information processing of pd patients in learning a new task. * whether autonomy supported learning can facilitate cortical excitability change after practicing a new task. participants will be recruited into two groups (self-control group, sc; and yoked group, yk) to learn a finger-pressing trajectory matching task * participants in sc group will have choice over feedback schedule during trial practice * participants in yk group will receive feedback with no-choice during trial practice researchers will compare the retention test performance to see if autonomy supported learning will lead to better learning effect.

autonomy is the sense of learner to actively participate in determining their own behaviour. the present study aims to investigate whether an autonomy supported practice (with self-controlled feedback) would benefit adults with parkinson's disease (pd), along with increased intrinsic motivation, information processing and cortical excitability. two groups of healthy adults and two groups of pd patients will be recruited to learn a finger-pressing trajectory matching task. participants will be allocated in either a self-control group (choice over feedback schedule), or a yoked group (receive feedback with no-choice). learning will be assessed on the second day and one week later, along with an error estimation of learners' own performance to represent their information processing ability. cortical excitability and inhibition will be assessed via transcranial magnetic stimulation as indicators of cortical plasticity. questionnaire regarding motivation will be assessed before and after practice trials. study hypothesized that individual with pd would benefit from autonomy supported learning, with better performance, enhanced motivation and information processing, associates with change of cortical excitability

Eligibility criteria:
inclusion criteria: * age above 20-years-old * able to follow instructions to perform the tasks (montreal cognitive assessment ≥ 24) * no surgery and injury in upper extremities in recent 6 months exclusion criteria: * other neurological disorders in addition to parkinson's disease * parkinson's disease dementia * symptom of severe tremor in upper extremities (score ≥ 3 in question 15 to 18 of updrs-iii) * deep brain stimulation or pacemaker implanted * medical history of seizure * a blood-relative with history of epilepsy * unstable medical conditions * pregnancy

Keywords: parkinson's disease autonomy motor learning transcranial magnetic stimulation
long term study of istradefylline in subjects with moderate to severe parkinson's disease

Conditions: Idiopathic Parkinson's Disease

Summary: this is a phase 3, 52-week, open-label, flexible-dose, multinational, multicenter study to evaluate the safety and tolerability of istradefylline 20 or 40 mg/d in subjects with moderate to severe pd with motor fluctuations and dyskinesia on levodopa combination (levodopa/carbidopa or levodopa/benserazide) therapy plus at least one adjunctive pd medication. subjects who completed 12 weeks of double-blind treatment and the 30-day follow-up period in study no. 6002-014 will undergo screening and baseline evaluations for eligibility for the study. eligible subjects will be treated with istradefylline at a starting dose of 20 mg/d with an option for a dose adjustment to 40 mg/d at week 12 based on the investigator's judgment of each subject's response and tolerability. if deemed necessary, one unscheduled dose adjustment visit between week 2 to week 12 is allowed in accordance with clinical judgment of the investigator. subjects who had a dose adjustment to 40 mg/d can have their dose decreased to 20 mg/d by the investigator at a second unscheduled dose adjustment visit if there are tolerability issues. the istradefylline dose should remain fixed between week 26 to week 52. consultation with the sponsor's medical monitor is required prior to any unscheduled dose adjustment visits. a subject may discontinue from the study at any time.


Eligibility criteria:
inclusion criteria: 1. written informed consent; 2. subjects who completed study no. 6002-014 inclusive of the 30-day follow-up period; 3. currently taking levodopa combination (carbidopa/levodopa or benserazide/levodopa) therapy plus at least one adjunctive pd medication; 4. women of child-bearing potential (wocbp) must use a reliable method of contraception and have a negative serum pregnancy test at screening; exclusion criteria: 1. subjects with less than 70% treatment compliance throughout their enrollment on study no 6002-014 and or with major protocol deviations in study no. 6002-014 (subjects who failed to meet any of the inclusion criteria, subjects who met any of the exclusion criteria or subjects who met the criteria for subject withdrawal but who were not withdrawn); 2. subjects on apomorphine and/or dopamine receptor antagonists or direct gastrointestinal levodopa infusion; 3. subject who have had neurosurgical operation for pd; 4. subjects taking a2a antagonist, potent cyp3a4 inhibitors, potent cyp34a inducers; 5. subjects who have had a diagnosis of cancer or evidence of continued malignancy within the past three years (with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or in situ prostate cancer with normal prostate-specific antigens post resection).

Keywords: parkinson's disease moderate to severe parkinson's disease